Definition
Norketamine (also written as nor-ketamine or desmethylketamine) is the primary active metabolite of ketamine, formed when the liver removes a methyl group from the ketamine molecule through a process called N-demethylation. This metabolic conversion is carried out primarily by cytochrome P450 enzymes CYP3A4 and CYP2B6 in the liver. Norketamine is pharmacologically active — it retains approximately one-third to one-fifth the potency of ketamine at the NMDA receptor — and may contribute meaningfully to the overall therapeutic effects of ketamine, particularly when the drug is administered orally.
How Norketamine Is Formed
The Metabolic Pathway
When ketamine enters the body, it undergoes biotransformation through a series of hepatic metabolic steps:
- N-demethylation: The primary metabolic step. Hepatic CYP3A4 and CYP2B6 enzymes remove a methyl group (CH3) from ketamine's nitrogen atom, producing norketamine. This is the most clinically significant metabolic step.
- Hydroxylation: Norketamine is further metabolized by hydroxylation at various positions on the cyclohexanone ring, producing hydroxynorketamine (HNK) metabolites. Multiple HNK variants exist, designated by the position of hydroxylation (e.g., (2R,6R)-hydroxynorketamine, (2S,6S)-hydroxynorketamine).
- Conjugation: Hydroxylated metabolites are conjugated with glucuronic acid to form water-soluble compounds that are excreted by the kidneys.
Route-Dependent Metabolite Ratios
The ratio of ketamine to norketamine in the bloodstream depends heavily on the administration route:
- Intravenous: Ketamine enters the systemic circulation directly, resulting in high initial parent drug levels with norketamine accumulating over time as metabolism proceeds. The peak ketamine-to-norketamine ratio favors the parent drug.
- Oral (swallowed): Extensive first-pass metabolism converts a large proportion of ketamine to norketamine before it reaches the systemic circulation. Oral administration results in norketamine plasma concentrations that may equal or exceed those of the parent drug. This is a critical pharmacokinetic distinction.
- Sublingual: Partial first-pass avoidance results in intermediate metabolite ratios — more parent drug than oral but less than IV. See oral and sublingual ketamine for details.
- Intramuscular: High bioavailability (~93%) means metabolite ratios are closer to IV than oral. See intramuscular ketamine.
Pharmacological Activity
NMDA Receptor Binding
Norketamine is an NMDA receptor antagonist, but with substantially lower affinity than the parent compound. Studies have estimated norketamine's potency at the NMDA receptor to be approximately 20 to 33 percent that of ketamine. Despite this reduced potency, norketamine's presence at significant plasma concentrations — particularly after oral dosing — means it likely contributes to the overall NMDA receptor blockade and, by extension, to clinical effects.
Analgesic Properties
Animal studies have demonstrated that norketamine has analgesic (pain-relieving) properties, though weaker than ketamine on a milligram-for-milligram basis. In the context of ketamine for chronic pain, norketamine may provide an additional layer of analgesia that extends the duration of effect beyond what the parent drug alone would produce.
Potential Antidepressant Activity
The question of whether norketamine contributes to ketamine's antidepressant effect is an active area of research. Some preclinical studies have reported antidepressant-like activity for norketamine in animal behavioral tests, though less robustly than ketamine itself. The clinical significance of norketamine's antidepressant contribution in humans remains uncertain. For a broader discussion of ketamine's mechanisms, see how ketamine works in the brain.
Hydroxynorketamine (HNK): The Next-Generation Metabolite
The HNK Hypothesis
In 2016, a landmark study by Zanos and colleagues generated significant attention by proposing that (2R,6R)-hydroxynorketamine — a further downstream metabolite of norketamine — might be responsible for a substantial portion of ketamine's antidepressant effects. The researchers found that this HNK metabolite produced antidepressant-like effects in mice without NMDA receptor blockade, dissociation, or abuse potential.
This finding was provocative because it suggested that the antidepressant and dissociative effects of ketamine could be separated — that the "active" antidepressant ingredient might not be ketamine itself but rather a metabolite that acts through a different mechanism, potentially involving AMPA receptor activation.
Ongoing Debate
The HNK hypothesis remains contested. Subsequent studies have produced mixed results, with some confirming and others failing to replicate the antidepressant-like effects of HNK in animal models. Additionally, some researchers have questioned whether HNK reaches sufficient brain concentrations in humans to produce pharmacologically meaningful effects. Clinical trials of synthetic HNK formulations are underway and may provide definitive answers.
The relationship between norketamine and HNK is relevant because norketamine serves as the obligate precursor to HNK — without N-demethylation to norketamine first, the HNK metabolites cannot be formed.
Enantiomeric Considerations
Like ketamine itself, norketamine exists as two enantiomers:
- S-norketamine: Formed from S-ketamine (esketamine), with higher NMDA receptor affinity
- R-norketamine: Formed from R-ketamine (arketamine), with lower NMDA receptor affinity
When racemic ketamine is administered, both enantiomeric forms of norketamine are produced. However, S-ketamine is metabolized more rapidly than R-ketamine, meaning S-norketamine accumulates faster. Over time, the relative proportions of the two norketamine enantiomers shift, creating a dynamic metabolite profile that differs from the initial racemic composition of the parent drug.
Clinical Significance
Why Norketamine Matters for Oral Ketamine
The clinical relevance of norketamine is greatest for patients receiving oral ketamine formulations. Because first-pass metabolism converts a large proportion of the oral dose to norketamine before it reaches the brain, oral ketamine patients are effectively being treated with a combination of ketamine and norketamine. This is fundamentally different from IV infusion patients, who experience predominantly ketamine with norketamine accumulating secondarily.
This pharmacokinetic difference may help explain clinical observations that:
- Oral ketamine produces less dissociation than IV ketamine at equi-analgesic doses (because norketamine is less dissociative than ketamine)
- Oral ketamine may have a longer duration of analgesic effect (because norketamine, while less potent, has a longer half-life)
- The subjective experience of oral versus IV ketamine differs qualitatively, not just quantitatively
Drug Testing Considerations
Norketamine is detected by standard urine drug testing for ketamine. Both ketamine and norketamine are identified in clinical and forensic toxicology panels. Norketamine's longer half-life means it remains detectable in urine for longer than the parent drug — typically 7 to 14 days after a single dose, compared to 2 to 4 days for ketamine. Patients undergoing regular ketamine therapy should be aware that norketamine may produce positive drug test results for an extended period. For more on ketamine's legal status, see is ketamine legal?.
Half-Life
Norketamine has an elimination half-life of approximately 4 to 6 hours, roughly twice that of ketamine (2 to 3 hours). This longer half-life means norketamine remains in the body longer than the parent drug, potentially extending the duration of pharmacological activity. In patients receiving repeated doses, norketamine may accumulate to a greater degree than ketamine.
Norketamine in Drug Development
Understanding norketamine's pharmacology has influenced the development of next-generation ketamine-derived treatments:
- Prodrug approaches: Some drug development programs are exploring compounds designed to be converted to norketamine or HNK in the body, potentially offering antidepressant effects without the dissociative and psychotomimetic effects of ketamine
- Metabolite-based therapies: Direct administration of specific HNK metabolites is being investigated as a strategy to bypass both ketamine and norketamine and deliver only the putatively antidepressant metabolite
- Metabolism-modifying strategies: Understanding which CYP enzymes produce norketamine has raised the possibility of co-administering CYP modulators to alter the ketamine-to-norketamine ratio and optimize therapeutic effects
Summary
Norketamine is far more than a pharmacological footnote — it is a clinically relevant active metabolite that contributes to ketamine's therapeutic profile, particularly in oral formulations where first-pass metabolism ensures high norketamine concentrations. With its own NMDA receptor activity, its role as the precursor to the potentially antidepressant HNK metabolites, and its influence on the duration and character of ketamine's clinical effects, norketamine is an essential piece of the ketamine pharmacology puzzle.
References
- Zanos P, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews, 2018 — Comprehensive review of ketamine and metabolite pharmacology
- Zanos P, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 2016 — The landmark HNK study proposing metabolite-driven antidepressant effects
- Ketamine Pharmacokinetics — National Center for Biotechnology Information (NCBI) — Reference on ketamine absorption, distribution, metabolism, and excretion
- Desta Z, et al. Stereoselective pharmacokinetics of racemic ketamine and norketamine. Xenobiotica, 2012 — Enantiomer-specific metabolic data
- Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates. Psychiatry and Clinical Neurosciences, 2019 — Overview of the role of metabolites in ketamine's antidepressant mechanism
Share